Moreover, the IFN signature (including IFI44L and other genes) can predict the sensitivity of RA patients to rituximab (RTX) with excellent ROC analysis (an AUC of 0.87) (102). The gene discussed is IFI44L; the disease is rheumatoid arthritis.